Pfizer Inc. Cuts A $190 Million Settlement Deal Over Epilepsy Drug Neurontin
Published: Apr 22, 2014
(Reuters) - Pfizer Inc has agreed to pay $190 million to settle a class-action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.
Lawyers representing a class of Neurontin purchasers disclosed the terms of the settlement in a motion filed in New Jersey federal court seeking approval of the deal.
Help employers find you! Check out all the jobs and post your resume.